LATE COMPLICATIONS AFTER AUTOLOGOUS HSCT FOR AUTOIMMUNE DISEASES: a retrospective survey from the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Study type:

Retrospective Studies

Study number:

8410-028

Type of Stem Cell Treatment:

Autologous

Diseases:

Short title:

LEAD

Primary objective:

To describe the cumulative incidence, nature, and risk factors of late effects in patients (both adults and children) after receiving auto-HSCT for AD. The study will focus on newly occurring cancers, secondary autoimmune diseases, cardiovascular events, endocrine/reproductive failure and bone events occurring at any stage following autologous HSCT. In addition assessment will be made of late mortality from any cause and performance status. Such information will inform the basis for future controlled analyses in this field.

Key inclusion criteria:

- First autologous HSCT performed for AD between 1997 and 2016
- Any diagnosis of AD

Country:

Principal investigator:

Kirill Kirgizov

EBMT Study coordinator:

Manuela Badoglio

Study coordinator email:

manuela.badoglio@upmc.fr